Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1-S Transition.
Buck SAJ, Van Hemelryk A, de Ridder C, Stuurman D, Erkens-Schulze S, van 't Geloof S, Teubel WJ, Koolen SLW, Martens-Uzunova ES, van Royen ME, de Wit R, Mathijssen RHJ, van Weerden WM. Buck SAJ, et al. Among authors: mathijssen rhj. Mol Cancer Ther. 2024 May 2;23(5):711-720. doi: 10.1158/1535-7163.MCT-23-0420. Mol Cancer Ther. 2024. PMID: 38030379
Danusertib, an aurora kinase inhibitor.
Meulenbeld HJ, Mathijssen RH, Verweij J, de Wit R, de Jonge MJ. Meulenbeld HJ, et al. Expert Opin Investig Drugs. 2012 Mar;21(3):383-93. doi: 10.1517/13543784.2012.652303. Epub 2012 Jan 13. Expert Opin Investig Drugs. 2012. PMID: 22242557 Review.
Inter-patient variability in docetaxel pharmacokinetics: A review.
Nieuweboer AJ, de Morrée ES, de Graan AJ, Sparreboom A, de Wit R, Mathijssen RH. Nieuweboer AJ, et al. Cancer Treat Rev. 2015 Jul;41(7):605-13. doi: 10.1016/j.ctrv.2015.04.012. Epub 2015 May 7. Cancer Treat Rev. 2015. PMID: 25980322 Review.
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.
Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S. Onstenk W, et al. Eur Urol. 2015 Dec;68(6):939-45. doi: 10.1016/j.eururo.2015.07.007. Epub 2015 Jul 15. Eur Urol. 2015. PMID: 26188394 Clinical Trial.
Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
van Soest RJ, de Morrée ES, Kweldam CF, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM. van Soest RJ, et al. Eur Urol. 2016 Mar;69(3):e43-4. doi: 10.1016/j.eururo.2015.07.024. Epub 2015 Jul 30. Eur Urol. 2016. PMID: 26233533 No abstract available.
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
van Soest RJ, Nieuweboer AJ, de Morrée ES, Chitu D, Bergman AM, Goey SH, Bos MM, van der Meer N, Hamberg P, de Wit R, Mathijssen RH; Dutch Uro-Oncology Studygroup (DUOS). van Soest RJ, et al. Eur J Cancer. 2015 Nov;51(17):2562-9. doi: 10.1016/j.ejca.2015.07.037. Epub 2015 Aug 13. Eur J Cancer. 2015. PMID: 26278646 Clinical Trial.
Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.
Nieuweboer AJ, Smid M, de Graan AM, Elbouazzaoui S, de Bruijn P, Eskens FA, Hamberg P, Martens JW, Sparreboom A, de Wit R, van Schaik RH, Mathijssen RH. Nieuweboer AJ, et al. Pharmacogenomics J. 2016 Nov;16(6):519-524. doi: 10.1038/tpj.2015.66. Epub 2015 Sep 8. Pharmacogenomics J. 2016. PMID: 26345519
361 results